Accendatech (hereinafter referred to as the ”Company”) was established in 2008. The company has received support from major national new drug creation projects and has created a technology platform for crossing the blood-brain barrier and a drug research and development platform targeting cancer stem cells. In response to the most urgent clinical needs, we have carried out research and development, trial production and clinical trials at home and abroad of global original new drugs. The company has currently developed a number of new drug candidates, among which the exclusively developed small molecule immunomodulator ACT001 can cross the blood-brain barrier well and enter the brain in large quantities. Immune modulators (such as lenalidomide) often have broad application prospects in cancer, inflammation and fibrosis. However, among drug candidates on the market and in clinical trials globally, immunomodulators that can enter the brain are very rare. ACT001 obtained U.S. orphan drug status in 2017 and was one of the top 10 products in my country to obtain FDA orphan drug status. In 2018, it obtained EU orphan drug status without defense. In 2021, ACT001 obtained the rare childhood disease qualification approved by the US FDA, which is the first rare childhood disease qualification independently developed in China. The results of ACT001 related clinical trials were published in posters at three ASCO conferences in 2018/2021, as well as lecture reports at the SNO conference in 2021. ACT001 has been approved for 8 1b/2a or phase 2 clinical trials and 1 phase 2b/3 clinical trial in China, the United States and Australia. The company is not only engaged in the development of new drugs for refractory rare diseases and rare diseases in children, but also vigorously promotes the expansion of indications with broad market prospects, urgent clinical needs and few competitive drugs, including radiotherapy to treat attenuation and sensitivity, organ fibrosis, etc. . Suntech